Home / Science / AI Predicts Bowel Cancer Drug Success
AI Predicts Bowel Cancer Drug Success
14 Apr
Summary
- New AI model identifies patients benefiting from bowel cancer drug.
- AI integrates tumor genetics and patient data for predictions.
- Research aims to prevent ineffective treatments and side effects.
A groundbreaking AI model named PhenMap has been developed to identify patients most likely to benefit from bevacizumab, a targeted drug now available on the NHS for advanced bowel cancer. Developed by researchers in London and Dublin, this AI integrates complex data, including tumor genetic makeup and patient clinical information like age and gender.
Previously, cancer subtypes were broadly categorized. PhenMap, however, can detect more intricate patterns, creating a more precise patient stratification. This innovation aims to prevent patients from undergoing treatments that are unlikely to be effective, thereby avoiding unnecessary side effects.
Researchers analyzed data from 117 European patients treated with bevacizumab and chemotherapy. The findings, published in Scientific Reports, require validation in larger patient groups. This AI approach holds potential for predicting responses to other targeted therapies across various cancer types.
